Purpose: Evaluating the extent of and the factors affecting marginal bone level (MBL) alterations and consecutively implant success and implant health for implants placed in staged maxillary sinus floor (SF) augmentation.
| INTRODUCTION
The use of dental implants for the implant-prosthodontic rehabilitaton of the posterior maxilla is often limited by compromised bone quality and quantity. 1, 2 Maxillary sinus enlargement and alveolar ridge resorption as a result of tooth loss may necessitate a sinus augmentation procedure in preparation of dental implant placement. [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] Subantral bone regeneration, also known as maxillary sinus lift/augmentation was introduced by Boyne and James 7 and Tatum 8 and has been successfully used for more than 30 years. Regardless of the various techniques and approaches as well as the different grafting materials used for filling the sinus cavity, the implant-prosthodontic outcome is still of particular interest as it will determine the long-term course and has been the subject of numerous evaluations. 4, 5, [10] [11] [12] [13] [14] [15] [16] [17] However, the success rate of dental implants placed in the augmented maxillary sinus augmentation may be affected by intraoperative and/or postoperative augmentation complications or by the clinical course of the implants following dental implant osseointegration. 13, [18] [19] [20] [21] Among the intraoperative complications, sinus membrane perforation (SMP) and bleeding from the superior alveolar arteries are the most frequent ones encountered with the lateral window technique for sinus floor elevation (SFE). 20, 21 Although some authors found no negative influence on subsequent implant placement and implant/prosthodontic outcome, several other reports described a negative effect of membrane perforation on implant outcome which appears to be predominantly determined and influenced by the membrane perforation size 17, 21 .
Following successful osseointegration, it is predominantly biological complications that have the potential to induce or increase the loss of soft and/or hard (bone) peri-implant tissue and thereby influence the postinsertion course of the implants placed. [22] [23] [24] [25] [26] [27] A prolonged bone loss process may eventually lead to implant loss and may be predominantly be determined in terms of peri-implantitis and peri-implant mucositis. 25, 26 According to the definition of peri-implant disease (mucositis/peri-implantitis) assessment of peri-implant marginal bone level (MBL) alterations represents an important landmark, allowing for the identification of biological complications and subsequent implant health and success. 25, 26 Peri-implant MBL alteration is a result of the bone remodeling process and a well-investigated and recognized phenomenon which has to be considered as a bone-level change influenced by implant-, clinician-, and patient-related factors. [23] [24] [25] [26] [27] [28] For the postoperative bone remodeling process, several factors such as implant type, implant positioning, and different surgical procedures followed by different prosthodontic procedures may be distinguished. 27, 28 In several studies, the remodeling of the bone contour and additional annual bone loss during the following years were considered as an acceptable healing outcome. 23, 24, 29 Although the amount of peri-implant marginal bone resorption was used for defining implant success and implant health in numerous cross-sectional and retrospective studies, 24, 29 detailed reports on factors affecting the peri-implant MBL alteration with focus on implants placed in staged sinus augmentations are rare. In particular, there is a lack of prospective long-term reports evaluating the different effects of patient-, implant-, and clinician-/surgery-related factors affecting MBL alteration. 16, 17, 22 In addition, detailed evaluation of peri-implant soft tissue disease expressed as implant health (mucositis/peri-implantitis) for a homogeneous group of implant prosthodontic rehabilitation as staged SFE is lacking.
The primary aim of the present study was to evaluate the extent of peri-implant MBL alterations for implants placed in staged maxillary sinus augmentation procedures during a 5-year prospective follow-up period. The secondary aim was to evaluate overall implant and prostheses survival rate as well as a detailed risk anaylsis for factors affecting MBL alterations. In addition, the incidence of peri-implant disease (peri-implantitis and peri-implant mucositis) and the implant success rate was assessed. The initial working hypothesis was that systemic patient-related risk factors might have more influence on peri-implant MBL alterations than implant-or clinician-/surgery-related factors in association with implant placement in SFE procedures.
| MATERIALS AND METHODS

| Patient selection
The study was designed as a single-center (private practice), 5-year, (Table 1) who met the inclusion criteria (Table 2) were included and had 124 staged SFE procedures. All patients were given a detailed description of the procedures and provided written informed consent before inclusion. The investigation was conducted according to the principles of the Helsinki Declaration for biomedical research involving human subjects. The study protocol had been approved by the local ethics committee (Upper Austria, UAE-06136) and was self-funded by the authors. The
Strengthening the Report of Observational Studies in Epidemiology guidelines for reporting cohort studies were adhered to in the preparation of the article.
| Surgical procedures 2.2.1 | Sinus augmentation/bone grafting
One day before the surgical procedure, all patients (n = 85) were given 1 g of amoxicillin (orally), and immediately prior to surgery, they rinsed their mouth for 2 minutes with a 0.2% clorhexidine solution. All surgical procedures (n = 124) were performed by the same experienced surgeon (>20 years experience) under general or local anesthesia with concomitant sedation (G.K). A mid-crestal incision was done, and vertical releasing incisions were additionally placed anteriorly (canine area) and posteriorly next to the tuberosity. A mucoperiosteal flap was lifted allowing surgical access to the lateral sinus wall. Using round burs mounted on a contra angle handpiece (Elcomed, W&H, Bürmoos, Austria) an osteotomy of the facial sinus wall was performed as described in previous studies. 13, 22 The bony window was completely removed and the bone debris was harvested with a bone collector (Friadent, Dentsply, Mannheim, Germany). After completion of the osteotomy with the piezosurgical unit, the sinus membrane was lifted with hand instruments superiorly starting from the superior border of the osteotomy site following the complete and careful dissection from the medial, posterior, and inferior walls of the sinus cavity. The sinus membrane was lifted carefully to allow for placement of implants 13 to 16 mm in length, and Valsalva pressure was taken to control consistent opening of sinus ostium (ventilation) and avoid occlusion of the ostium.
Before grafting the sinus cavity, the elevated Schneiderian membrane was thickened and covered with a bioresorbable porcinederived collagen membrane (Bio-Gide, Geistlich Pharma, Wolhusen, Switzerland) to close invisible minimal perforations. For sinus grafting, the augmentation procedures were done using a mixture of bovine bone mineral (BBM, Bio-Oss, granular size: 0.25-1 mm, Geistlich
Pharma, Wolhusen, Switzerland) with venous blood and with different amounts (20%-50%) of autogenous bone harvested from different intraoral/extroral donor sites (local osteotomy/retromolar/iliac/tibia graft). Graft mixture ratio consisting of autogenous bone and BBM were calibrated using a 10 mL syringe.
After sinus grafting, the lateral access window was then also covered with Bio-Gide to prevent soft tissue invasion and to promote bone formation. Thus, the Bio-Gide membrane was trimmed to cover the osteotomy window, extending 2-3 mm beyond its borders, and it was occasionally fixed with titanium pins (FriOss, Dentsply, Mannheim, Germany). The mucoperiosteal flap was repositioned and sutured using resorbable and nonresorbable suture material to achieve closure of a tension-free flap (5.0 Vicryl; Ethicon, Johnson & Johnson, Germany). Postoperatively, patients were given amoxicillin (500 mg three times/day for 7 days) and ibuprofen 600 mg every 8-12 hours.
All patients were instructed to rinse twice daily over a period of 2 weeks using a 0.12% chlorhexidine gluconate solution and to use a nasal decongestant twice a day for 10 days. They were also advised not to blow their noses for 10 days until the sutures were removed. All implants were placed at the crestal level and were left submerged for a mean healing period of 5-7 months prior to abutment connection. 
| Implant placement
| Prosthodontic treatment
| Clinical analysis
Patients were enrolled in a regular hygiene program (annually) and 
| Primary outcome measures
The assessment of peri-implant MBL alteration was the main dependent variable. Using a digital imaging system (Orthophos XGPlus, Sidexis, Siemens, Sirona Dental System, Bensheim, Germany) peri-implant MBL alteration (mm) was assessed radiographically and an independent outcome assessor (K.S.) trained and experienced in radiographic measuring and not being aware of the study design made all measurements. In several cases with doubtful measurements (n = 14 implants), experienced periodontists (K.G.) assisted the assessor to find results for calculation.
The radiographic measurements were made with a single periapical radiograph with the paralleling technique (long cone) determining the bone height level in relation to the implant shoulder as reference point. The initial postoperative radiographs (baseline radiographs)
were compared with the 1-, 3-, and 5-year postloading radiographs for calculating the effective peri-implant MBL change and the periimplant marginal bone loss was calculated as the result of the difference. 31 In implants, bone loss was measured on the mesial and distal side for each implant with the worst (highest) marginal bone resorption on the implant being used for rating.
| Secondary outcome measures
1. Implant and prosthesis survival rates: Implants placed being in situ at the follow-up examinations were rated as survivors. Prosthesis survival rate was assumed when the prosthesis could be placed, did not need to be replaced with a new or alternative prosthesis and could be followed up (with or without technical/prosthodontics complications) during the 5-year follow-up period. Implant stability was assessed using the metallic handles of two instruments when prothese were inserted or had to be removed for cleaning/repair.
2. Risk factor analysis affecting marginal bone loss was assessed (1 unit, 2 unit, 3 or >3 unit) were assessed. One-unit restorations corresponded to ST restorations and two-unit restorations were used as fixed restoration; 3-unit restorations were either used for FPDs (3 unit FPD) or as a part of a FAD restoration; FADs were used either for removable or for fixed dentures. The opposite dentition was assessed as follows: natural dentition (NT), fixed or removable partial dentures (FPD, RPD) or as edentulous region (complete dentures wearer).
3. Assessment of implant health at the year 1, year 3, and year 5 postloading follow-up included the evaluation of biological complications by clinical examination by an independent assessor (MW) and the results of this assessment were defined as follows.
• Bleeding on probing (BOP): a score of "0" was assigned when there was no bleeding for up to 5 seconds after probing, and "1"
when bleeding occurred.
• Definition of peri-implant mucositis and peri-implantitis: Diagnostic criteria previously reported for peri-implantitis and periimplant mucositis were used. 25, 26 Peri-implant mucositis was defined as presence of at least one implant surface with positive BOP. Peri-implantitis was diagnosed when an implant had simultaneously positive BOP and radiographically detectable marginal bone loss >2.0 mm. Presence of gingiva hyperplasia and/or fistulas was accounted for at least peri-implant mucositis.
23,26
• Plaque score: As for BOP records, plaque was assessed as a binary (0 or 1) outcome.
• Pocket probing depth (PPD): PPD was measured at four sites were assessed annually when prostheses were removed for denture cleaning or repair.
• Dimension of keratinized mucosa (mm) was measured with a periodontal probe (CP12, Hu-Friedy, Chicago, Illinois).
4. Criteria for implant success rates: Those implants meeting the following criteria were considered as successful implants 27,32 :
(1) absence of persistent pain, (2) 
| Statistical analysis
Qualitative variables were expressed as frequencies and percentages. 3 | RESULTS 
| Patients/drop out
| MBL alterations
For the overall sample population evaluated, the MBL alteration was 1.45 AE 0.38 mm. Figure 2 presents MBL alteration at the year 1, year 3, and year 5 evaluation, showing significant MBL reduction over time (P < .001). found for the location of implant placement (premolar vs molar region; P = .640) and for the kind of opposite dentures present (P = .684). removable ×1, fixed ×1) implants were removed and prostheses stabilized on the remaining implants.
| Implant/prosthesis survival
| Factors affecting MBL alterations
Results of multivariate analysis presenting factors affecting MBL alterations are shown in Table 4 . There is an relationship for time (1 year vs 5 years: P = .001; OR = 6.888; 1 year vs 3 years: P = .001;OR = FIGURE 2 MBL alteration at the first, third, and fifth year evaluation Risk factors affecting MBL alterations were significantly greater for a 3 (>3) units gaps than for ST replacemant (P < .001; OR = 13.455).
Within the ≥3-unit gaps, implants placed for the use of a FAD were found to be a significantly higher risk as factors than ≥3-unit gaps used for a FPD (P < 0.001, OR = 8.275).
| Peri-implant health (peri-implant mucositis/ peri-impantitis)-Implant success
Considering the defined threshold, the overall incidence of healthy implants was 71% at implant and 63% at patient level for the 5-year observation period. The overall 5-year incidence of peri-implant mucositis and peri-implantitis was 25.3% and 3.7% at implant level and 30.3% and 6.6% at patient level, respectively. As additional finding for implant health, there were two implants showing bone loss without bleeding as a sign of healed sites after undergoing previous peri-implantitis. These implants were considered as failures and were rated as nonsuccessful. Table 5 shows detailed information on implant survival and success rate as well as implant health and implant disease (mucostitis/peri-implantitis) at year 1, year 3, and year 5 evaluation at implant and patient based level.
For all implants followed, the overall PPD was 2.64 mm (SD:
0.73 mm) at the year 1, 2.55 mm (SD: 0.68 mm) at the year 3, and 2.59 mm (SD: 0.70 mm) at the year 5 evaluation without significant differences over the observation period. All implants were covered with keratinized gingiva of at least 2 mm on buccal side and all implants were covered with fixed palatal mucosa.
| Power of the study
The results in the primary outcome measured as implant survival over the 5 years was used as a surrogate endpoint for calculating the posthoc power analysis of the study using a sample-size-estimation algorithm for the chi-square test. The sample size was determined by the duration of the study. Based on this surrogate endpoint, the poweranalysis for year 5 yielded the following results (each P value > .05):
implant-based survival: power = 84.1%, implant-based success: power = 80%, and implant-based peri-implantitis: power = 80%.
| DISCUSSION
The present prospective study focuses on the analysis of peri-implant MBL alteration and factors potentially involved in this process for implants placed in staged maxillary sinus augmentation procedures.
The study assessed the extent of and the influences for MBL alterations, a feature included in the definition of dental implant success criteria, as well as the prevalence of implant disease expressed as peri-implant mucositis and, especially, peri-implantitis. [23] [24] [25] [26] It is a fact that a minor degree of radiographically determined peri-implant marginal alveolar bone loss represents a commonly observed and clinically accepted phenomenon in dental implant treatment. 23, 27 Within the wide range of the heterogeneity of reasons for MBL alterations as described by Albrektsson and colleagues, 27 factors affecting periimplant bone loss may be attributed either to patient-and/or clinician-/surgery-related as well as to prosthesis-related factors. 27, 28 Considering the numerous risk factors evaluated, the present study was partially able to confirm the null hypothesis that patientrelated risk factors are more prone to show an impact on peri-implant MBL alteration and may thus affect implant success and implant health to a greater extent than prosthetic or surgery/clinician factors.
Considering the similarity of maxillary alveolar ridge atrophy and the identical surgical technique used for staged SFE, the homogenity of the population evaluated allowed appropriate comparison and evaluation of different risk factors.
In the present prospective study, the overall radiographically monitored peri-implant MBL alterations found were similar to findings previously reported for screw type implants with internal connection. 29, 30, 34, 35 Dental implants placed in staged SFE showed an initial MBL alteration confirming the bone remodeling process as described in reports of Albrektsson and colleagues, 27 Roos and colleagues, 36 Røynesdal and colleagues, 37 and Bornstein and colleagues. 22 The extensive initial bone loss occurring in the period between implant uncovering to the first year of follow-up evaluation is likely to be the result of the biologic width formation around the implants. [38] [39] [40] However, regardless of the risk factors evaluated, an OR = 6.888 defined a significant MBL alteration over 5 years without differences between premolar and molar sites. The findings obtained are consistent with previously published research suggesting that the longer the implant has been in function the more likely it will show MBL. 41, 42 This is possibly as a result of the increased exposure time to exogenous agents, such as tobacco and pathogenic microorganisms causing MBL alterations. [42] [43] [44] But already in the univariate analysis a significantly higher marginal bone reduction was noticed for patients with smoking status, history of previous periodontal diseases, and the presence of plaque score. The risk characteristics of patients-related factors as smoking status (OR = 6.563) and the history of periodontal disease (OR = 4.450) affecting MBL reduction were additionally confirmed in the multivariate analysis and also expressed with significant ORs (P < .001; P < .015). As already reported from several previous studies, smoking is known to cause increased marginal bone loss around implants, which is predominantly because of the influence of tobacco smoking on specific hormones and enzymes regulating bone metabolism and decreasing alkaline phosphatase activity. [42] [43] [44] The other significant patient-related factor associated with increased peri-implant MBL alterations include a history of previous periodontal disease as reason for tooth loss with subsequent augmentation and implant procedures. [45] [46] [47] [48] This is consistent with recent retrospective reports describing a higher risk profile for patients having implants placed in regions previously affected by periodontal disease although the sites had been surgically treated and are presented as healed ones. 45 However, among the patient-related factors affecting MBL alterations, the present study showed no correlation for age and gender, as previously reported. 48, 49 The present study presented no correlation with (controlled) type 2 diabetes mellitus diseases and rheumatic disorders. This might be attributed to the low incidence in the population evaluated and the successful treatment of hyperglycaemia with resultant acceptable Hba1c values. 50, 51 However, additionally to the patient-specific factors affecting MBL alterations, the present study was also able to show that and colleagues. 45 Thus, the reason for tooth loss, the resulting alveolar residual ridge height, and the prosthodontic use of the dental implant as well as the patient-related risk factors present must be considered in context to explain the MBL alteration. [44] [45] [46] [47] [48] [49] In the context of the MBL alterations found, it was noted that after a follow-up of 5 years, healthy peri-implant conditions were noted in about 63% of the patients, corresponding to 71% at the implant level. While peri-implant mucositis was diagnosed in 30.3% of the patients, the incidence of peri-implantitis was 6.6% corresponding to 25.3% and 3.7% at the implant level, respectively. Within the limitations of the study, it must be emphasized that the results were derived using a very strict definition. 25, 26 Nevertheless, the frequency of patients diagnosed with peri-implant disease seemed to be below the prevalence range calculated in previous systematic reviews 26 or cross-sectional studies. 24, 29 However, it must be noted that the reported prevalence of peri-implantitis shows a high degree of variability ranging from 1.8% 32 to 47.1% 55 which may mainly be attributed to heterogeneous case definitions and thresholds for bone level alterations. As described by Schwarz and colleagues, 29 the plaque score was significantly associated with pronounced MBL alterations also in the present study. However, the lack of an extensive progression of MBL alterations may be because of the regular recalls and the hygiene instructions provided. 23, 24, 29 Additionally, it can clearly be recognized that an increased width of the keratinized gingiva which was present in all patients/implants included is associated with a reduced likelihood of MBL alterations and, consequently, with a healthy peri-implant status.
28,56
Although the present study outcomes on implant survival rates are very similar to previous data ranging from 97% to 100% a distinction needs to be made between implant success rate (96.5%) and nonperi-implantitis rate (97.1%) found. [23] [24] [25] [26] [27] The success rates (96.5%) following Albrektsson's criteria 27 were very similar to previously published data, ranging from 93.3% to 96.5%. In the present study, two implants were considered as failures as a result of previous periimplantitis presenting a defect healing without peri-implant bleeding conditions at the last evaluation. Therefore, the implant success rate was lower than the non-peri-implantitis rate. [23] [24] [25] [26] [27] Within the limitations of the present study, it was concluded that peri-implant MBL alterations and consequently peri-implant implant health and implant success rate for implants placed in staged SFE procedures were predominately significantly correlated to patientspecific risk factors.
